Long-range supramolecular synthon polymorphism: a case study of two new polymorphic cocrystals of Ph₂Te₂–1,4-C₆F₄I₂

Abstract

Along with the reported earlier co-crystal of diphenyl ditelluride (Ph2Te2) and halogen bond donor 1,4-diiodo-tetrafluorobenzene (p-DITFB) 1α, its two new polymorphic forms (1β and 1γ) present a rare case of...

The relationship between the crystal habit and the energy framework pattern: a case study involving halogen bonding on the edge of a covalent bond

“…27 In our recent studies of the co-crystallization of diphenyl ditelluride or organometallic halides with the σand π-hole donors, we noted the relationship between the columnar or layered topology of the energy frameworks and the needle or the plate-like habits of the respective crystals. 28,29 In order to corroborate these relationships in the molecular co-crystals, we examined in the current work the associations of the iodo-dihalogens ICl, IBr, and I 2 with aliphatic and aromatic nucleophiles, in particular, 1,4-diazobicyclo[2,2,2]octane, pyridine, 2-bromopyridine, 4-dimethylaminopyridine and phenazine (abbreviated hereinafter as DABCO, Py, PyBr, PyNMe 2 and Phnz, respectively).…”

Analysis of short contacts in crystals of halogenated amino acids: atom–atom interactions vs. energy frameworks

“…This approach offers accurate computation of intermolecular interaction energies between molecular pairs in crystal structures and their visualization using colored cylinders, 37,41 and has been shown to be particularly useful in the analysis of weak interactions, such as hydrogen, halogen and chalcogen bonds. [42][43][44][45][46][47] These cylinders represent the energies between molecular pairs in crystals; the thicker the cylinder, the higher the interaction energy. Contributions of different types of intermolecular interactions (electrostatic, dispersion, polarization, repulsion) can be determined for each interacting molecular pair.…”

Drug–Drug Multicomponent Crystals of Epalrestat: A Novel Form of the Drug Combination and Improved Solubility and Photostability of Epalrestat

“…From the perspective of crystal engineering, drug–drug multicomponent crystals provide an effective method to solve the problems of FDCs. − Drug–drug multicomponent crystals refer to multicomponent solid crystalline supramolecular complexes composed of two or more APIs in the same lattice interacting through interactions . Due to the specific interactions in the crystal lattice, the physicochemical properties of the parent drugs may be improved, such as improving the dissolution behavior of at least one API, , enhancing the stability of unstable APIs, , which are expected to solve the dilemma of FDCs and further promote the bioavailability and therapeutic effect of the drug. − Moreover, studies have shown that drug–drug multicomponent crystals are an effective route to accelerate the development of the drug from preclinical studies to approved drugs. , For instance, the drug–drug multicomponent crystal product Entresto has a synergistic effect of 1 plus 1 greater than 2, which was approved by the US Food and Drug Administration (FDA) in 2015 for the treatment of chronic heart failure. , …”